Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
Medication Pearl of the Day: Upadacitinib (Rinvoq)
Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.
Insight:
Sources: